Update research from QuotedData

RNS Number : 9945M

Intl. Biotechnology Trust PLC

19 September 2019

 

International Biotechnology Trust plc - Update research from QuotedData

19th September 2019

Healthy yield attracts investors

The managers of International Biotechnology Trust (IBT) have focused its portfolio in oncology (cancer), diseases of the central nervous system and rare diseases - areas where pricing pressure on drugs and other therapies is less of an issue. This should cushion IBT as we approach election year in the US and (as is usually the case in the US political cycle) threats to intervene in drug pricing create volatility in the biotech sector.

Full research:https://quoteddata.com/research/international-biotechnology-trust-healthy-yield-attracts-investors/

This research is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

NB: this note has been prepared for International Biotechnology Trust by Marten & Co and is for information purposes only. It is not intended to encourage the reader to deal in the security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which is authorised and regulated by the FCA. Marten & Co is not permitted to provide investment advice to individual investors.

QUOTEDDATA
123a Kings Road | London SW3 4PL
Tel: [phone]

www.quoteddata.com | [e-mail] Helvetica, sans-serif; font-size: 10pt;">

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

 

END

 

 

NRAUKVARKRAKAAR